Join us as we continue this educational series through a new lens: Quality of Life. This webinar will cover the following topics:Emergency Care | Dr. Stefan Malin, MD, MSNavigating “Re-entry” […]
Learn more about REGENXBIO’s new gene therapy program for the potential treatment of Duchenne. This webinar provides an overview of the company and RGX-202, a novel, advanced micro-dystrophin gene therapy […]
This webinar provides an update from Astellas on their study to assess the safety, tolerability, and preliminary efficacy of ASP0367 (MA-0211) for boys with Duchenne Muscular Dystrophy. You’ll be prompted […]
PTC Therapeutics shared the below letter to the Duchenne community. We are pleased to see the results of the dystrophin study (Study 045) and thankful for PTC’s longtime commitment to […]
CureDuchenne’s webinar, COVID-19 Vaccines: What the Duchenne Community Needs to Know, was an opportunity for the Duchenne community to get reliable information on COVID-19 vaccines. A panel of experts from […]
NEWPORT BEACH, Calif., Jan. 14, 2021 – CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a new initiative centered on the COVID-19 vaccine rollout […]
Newport Beach, CA (January 08, 2021) – (BUSINESS WIRE)–CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), celebrates Pfizer Inc’s (NYSE: PFE) […]
CureDuchenne is pleased to share news that Avidity Biosciences has announced exciting details of its Duchenne program today, the full press release is below. CureDuchenne Ventures made an investment in […]
— Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo — — SRP-9001-treated participants showed […]
